实体恶性肿瘤中[68Ga]Ga-NODAGA-SNA006 PET显像CD8+ T细胞浸润的人体剂量递增研究
该人体剂量递增PET显像研究纳入11例实体恶性肿瘤患者(肺癌8例、胃癌1例、食管癌2例),给予约150 MBq不同纳米抗体质量(100、300、500、800 µg)的[68Ga]Ga-NODAGA-SNA006,于注射后15-30、60-90和120分钟行PET/CT。结果显示示踪剂耐受良好,脾脏摄取最高,肿瘤SUVmean与活检标本CD8+ T细胞浸润呈线性相关(R2=0.757,p=0.011)。
要点
- 11例实体瘤患者中[68Ga]Ga-NODAGA-SNA006耐受良好,脾脏摄取最高,其次为肾脏和膀胱。
- 肿瘤SUVmean与活检标本CD8+ T细胞浸润呈线性相关(R2=0.757,p=0.011)。
- 示踪剂从全血和血清中快速清除(t1/2<30 min),肝摄取随纳米抗体质量增加而降低。
核心结论
- [68Ga]Ga-NODAGA-SNA006使用安全、可行且耐受良好,其PET显像能准确检测肿瘤内CD8表达并具有良好药代动力学,为无创定量评估肿瘤CD8+ T细胞浸润和监测免疫治疗反应提供了可行方法。
研究设计与样本
- 人体剂量递增PET显像研究,纳入11例实体恶性肿瘤患者(肺癌8例、胃癌1例、食管癌2例)。
- 给予约150 MBq [68Ga]Ga-NODAGA-SNA006,纳米抗体质量分别为100 µg、300 µg、500 µg、800 µg。
- 于注射后15-30、60-90和120分钟行PET/CT扫描,评估生物分布、药代动力学和辐射剂量学。
- 通过免疫组织化学(IHC)测量活检样本CD8+ T细胞浸润,并与肿瘤摄取进行相关性分析。
主要发现
- [68Ga]Ga-NODAGA-SNA006在全部11例受试者中耐受良好。
- 最高放射性摄取见于脾脏,其次为肾脏和膀胱。
- 肝脏摄取随纳米抗体质量增加而降低。
- [68Ga]Ga-NODAGA-SNA006从全血和血清中快速清除(t1/2<30 min)。
- 肿瘤68Ga摄取(SUVmean)与活检样本CD8+ T细胞浸润呈线性关系(R2=0.757,p=0.011)。
关键数值与推荐
- 肿瘤SUVmean与活检样本CD8+ T细胞浸润线性相关:R2=0.757,p=0.011。
- 示踪剂从全血和血清清除的半衰期t1/2<30 min。
- 给药放射性活度约150 MBq,纳米抗体质量为100 µg、300 µg、500 µg、800 µg。
临床怎么用
- 原文结论认为[68Ga]Ga-NODAGA-SNA006 PET显像可为无创定量评估肿瘤CD8+ T细胞浸润和监测免疫治疗反应提供可行方法。
局限性
- 试验注册为回顾性注册(NCT05126927,2021年11月19日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A noninvasive method for evaluating the infiltration of CD8+ T cells in tumors is urgently needed to monitor the response to immunotherapy. This study investigated the performance of a [68Ga]Ga-NODAGA-SNA006 in positron emission tomography (PET) imaging of CD8+ T cells in patients with solid malignancies. METHODS: This human dose-escalation PET imaging study involved eleven patients (lung cancer, 8; gastric carcinoma, 1; esophageal carcinoma, 2). Approximately 150 MBq of [68Ga]Ga-NODAGA-SNA006 with varying nanobody masses (100 µg, 300 µg, 500 µg, 800 µg) was administered, and PET/computed tomography (CT) scans were performed at 15-30, 60-90 and 120 min postinjection (p.i.). Data regarding biodistribution, pharmacokinetics and radiation dosimetry were evaluated. CD8+ T-cell infiltration in biopsy samples was also measured via immunohistochemistry (IHC) for correlation analysis with the tumor uptake of [68Ga]Ga-NODAGA-SNA006 PET. RESULTS: [68Ga]Ga-NODAGA-SNA006 was well tolerated by all eleven subjects. The highest radioactive uptake was observed in the spleen, followed by the kidneys and bladder. Liver uptake decreased with increasing nanobody mass. Rapid clearance (t1/2<30 min) of [68Ga]Ga-NODAGA-SNA006 from whole blood and serum was observed. Furthermore, 68Ga uptake in tumors (SUVmean) exhibited a linear relationship with CD8+ T-cell infiltration in biopsy samples (R2 = 0.757, p = 0.011), suggesting that the tumor uptake of [68Ga]Ga-NODAGA-SNA006 may represent the degree of CD8+ T-cell infiltration in the tumor. CONCLUSION: The use of [68Ga]Ga-NODAGA-SNA006 is safe, feasible, and well tolerated. [68Ga]Ga-NONAGA-SNA006 PET imaging can accurately detect CD8 expression inside tumors with favorable pharmacokinetics, thus providing a feasible method for noninvasive quantitative assessment of CD8+ T-cell tumor infiltration and monitoring the response to immunotherapy. TRIAL REGISTRATION: NCT05126927 (19 November 2021, retrospectively registered).
引用
- Wang Y, Zheng M, Zhao J, et al. Human dose-escalation study of PET imaging CD8+ T-cell infiltration in solid malignancies with [68Ga]Ga -NODAGA-SNA006. Eur J Nucl Med Mol Imaging. 2024. PMID: 39653817. doi:10.1007/s00259-024-06999-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。